Meredith M Hoog, Carlos Vallarino, Juan M Maldonado, Michael Grabner, Chia-Chen Teng, Kendra Terrell, Emma L Richard
{"title":"替西帕肽与西马鲁肽对2型糖尿病患者HbA1c和体重的实际疗效","authors":"Meredith M Hoog, Carlos Vallarino, Juan M Maldonado, Michael Grabner, Chia-Chen Teng, Kendra Terrell, Emma L Richard","doi":"10.1007/s13300-025-01794-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management.</p><p><strong>Methods: </strong>This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023. GLP-1 RA naïve and non-naïve cohorts were identified based on the history of GLP-1 RA use within ≤ 6 months of initiation. Propensity score matching balanced 6-month baseline characteristics between groups. HbA1c and weight changes were assessed from initiation to 12 months for matched patients with HbA1c and weight data at both time points.</p><p><strong>Results: </strong>Both matched naïve cohorts were comprised of 10,702 patients (tirzepatide: 1399 with HbA1c data and 454 with weight data; semaglutide: 1173 with HbA1c data and 432 with weight data). Mean baseline HbA1c and weight were 7.8% and 112.4 kg, respectively, for the tirzepatide group and 7.8% and 110.7 kg for the semaglutide group. Both matched non-naïve cohorts were comprised of 5577 patients (tirzepatide: 792 with HbA1c data and 296 with weight data; semaglutide: 738 with HbA1c data and 224 with weight data). Mean baseline HbA1c and weight were 7.7% and 112.5 kg for tirzepatide, and 7.9% and 108.5 kg for semaglutide. Tirzepatide was associated with greater mean reductions in HbA1c (naïve: - 1.3% vs. - 0.9%; non-naïve: - 0.9% vs. - 0.6%; p < 0.001) and weight (naïve: - 10.2 kg vs. - 6.1 kg; non-naïve: - 7.9 kg vs. - 3.7 kg; p < 0.001) than semaglutide.</p><p><strong>Conclusions: </strong>Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.\",\"authors\":\"Meredith M Hoog, Carlos Vallarino, Juan M Maldonado, Michael Grabner, Chia-Chen Teng, Kendra Terrell, Emma L Richard\",\"doi\":\"10.1007/s13300-025-01794-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management.</p><p><strong>Methods: </strong>This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023. GLP-1 RA naïve and non-naïve cohorts were identified based on the history of GLP-1 RA use within ≤ 6 months of initiation. Propensity score matching balanced 6-month baseline characteristics between groups. HbA1c and weight changes were assessed from initiation to 12 months for matched patients with HbA1c and weight data at both time points.</p><p><strong>Results: </strong>Both matched naïve cohorts were comprised of 10,702 patients (tirzepatide: 1399 with HbA1c data and 454 with weight data; semaglutide: 1173 with HbA1c data and 432 with weight data). Mean baseline HbA1c and weight were 7.8% and 112.4 kg, respectively, for the tirzepatide group and 7.8% and 110.7 kg for the semaglutide group. Both matched non-naïve cohorts were comprised of 5577 patients (tirzepatide: 792 with HbA1c data and 296 with weight data; semaglutide: 738 with HbA1c data and 224 with weight data). Mean baseline HbA1c and weight were 7.7% and 112.5 kg for tirzepatide, and 7.9% and 108.5 kg for semaglutide. Tirzepatide was associated with greater mean reductions in HbA1c (naïve: - 1.3% vs. - 0.9%; non-naïve: - 0.9% vs. - 0.6%; p < 0.001) and weight (naïve: - 10.2 kg vs. - 6.1 kg; non-naïve: - 7.9 kg vs. - 3.7 kg; p < 0.001) than semaglutide.</p><p><strong>Conclusions: </strong>Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results.</p>\",\"PeriodicalId\":11192,\"journal\":{\"name\":\"Diabetes Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13300-025-01794-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-025-01794-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的：评估开始使用替西肽（双糖依赖性胰岛素性多肽和胰高血糖素样肽-1受体激动剂[GLP-1 RA]）或注射塞马鲁肽（GLP-1 RA）治疗2型糖尿病（T2D）的成人实际血红蛋白A1c （HbA1c）和体重变化。方法：本回顾性分析利用医疗保健综合研究数据库®识别2022年5月13日至2023年5月29日期间开始使用替西帕肽或注射用西马鲁肽的成人T2D患者。GLP-1 RA naïve和non-naïve队列是根据开始≤6个月的GLP-1 RA使用史确定的。倾向评分匹配各组间平衡的6个月基线特征。从起始到12个月，对具有两个时间点HbA1c和体重数据的匹配患者的HbA1c和体重变化进行评估。结果：两个匹配的naïve队列由10,702例患者组成（替西帕肽：1399例HbA1c数据，454例体重数据；西马鲁肽：1173例HbA1c数据，432例体重数据）。替西帕肽组的平均基线HbA1c和体重分别为7.8%和112.4 kg，西马鲁肽组为7.8%和110.7 kg。两个匹配的non-naïve队列由5577例患者组成（替西帕肽：792例HbA1c数据，296例体重数据；西马鲁肽：738例HbA1c数据，224例体重数据）。替西帕肽组的平均基线HbA1c和体重分别为7.7%和112.5 kg，西马鲁肽组的平均基线HbA1c和体重分别为7.9%和108.5 kg。替西帕肽与更大的平均HbA1c降低相关(naïve: - 1.3% vs. - 0.9%; non-naïve: - 0.9% vs. - 0.6%； p结论：与注射semaglutide的患者相比，在开始治疗后12个月，替西帕肽的t2dm患者的HbA1c和体重下降更大，与先前的GLP-1 RA使用情况无关，与先前的临床试验结果一致。
Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.
Introduction: To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management.
Methods: This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023. GLP-1 RA naïve and non-naïve cohorts were identified based on the history of GLP-1 RA use within ≤ 6 months of initiation. Propensity score matching balanced 6-month baseline characteristics between groups. HbA1c and weight changes were assessed from initiation to 12 months for matched patients with HbA1c and weight data at both time points.
Results: Both matched naïve cohorts were comprised of 10,702 patients (tirzepatide: 1399 with HbA1c data and 454 with weight data; semaglutide: 1173 with HbA1c data and 432 with weight data). Mean baseline HbA1c and weight were 7.8% and 112.4 kg, respectively, for the tirzepatide group and 7.8% and 110.7 kg for the semaglutide group. Both matched non-naïve cohorts were comprised of 5577 patients (tirzepatide: 792 with HbA1c data and 296 with weight data; semaglutide: 738 with HbA1c data and 224 with weight data). Mean baseline HbA1c and weight were 7.7% and 112.5 kg for tirzepatide, and 7.9% and 108.5 kg for semaglutide. Tirzepatide was associated with greater mean reductions in HbA1c (naïve: - 1.3% vs. - 0.9%; non-naïve: - 0.9% vs. - 0.6%; p < 0.001) and weight (naïve: - 10.2 kg vs. - 6.1 kg; non-naïve: - 7.9 kg vs. - 3.7 kg; p < 0.001) than semaglutide.
Conclusions: Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results.
期刊介绍：
Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
